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Abstract
Background
Magnetocardiography (MCG) is a non-invasive technique used to measure and map cardiac
magnetic fields. We describe the predictive performance of a portable prototype magnetometer
designed for use in acute and routine clinical settings. We assessed the predictive ability of the
measurements derived from the magnetometer for the ruling-out of healthy subjects and pa-
tients whose chest pain has a non-ischemic origin from those with ischemic heart disease (IHD).
Methods
MCG data were analyzed from a technical performance study, a pilot clinical study, and a
young healthy reference group. Participants were grouped to enable differentiation of those
with IHD versus non-IHD versus controls: Group A (70 IHD patients); Group B (69 controls);
Group C (37 young healthy volunteers). Scans were recorded in an unshielded room.
Between-group differences were explored using analysis of variance. The ability of 10 candi-
date MCG predictors to predict normal/abnormal cases was analyzed using logistic regression.
Predictive performance was internally validated using repeated five-fold cross-validation.
Results
Three MCG predictors showed a significant difference between patients and age-matched
controls (P<0.001); eight predictors showed a significant difference between patients and
young healthy volunteers (P<0.001). Logistic regression comparing patients with controls
yielded a specificity of 35.0%, sensitivity of 95.4%, and negative predictive value for the rul-
ing-out of IHD of 97.8% (area under the curve 0.78).
Conclusion
This analysis represents a preliminary indication that the portable magnetometer can help
rule-out healthy subjects and patients whose chest pain has a non-ischemic origin from
those with IHD.
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Introduction
Distinguishing between acute coronary syndrome (ACS) and non-cardiac chest pain is a
major challenge in the emergency department (ED) [1]. Current diagnostic tests for patients
presenting with chest pain are time-consuming and involve an electrocardiogram (ECG), as
well as serial blood biomarker testing [2]. Yet, almost 75% of patients with chest pain of a non-
cardiac origin are triaged through this pathway [3–5]. The ability to rule-out ACS earlier
would greatly improve patient care and hospital resource utilization [5]. Furthermore, current
diagnostics fail to detect up to 2% of non-ST-elevated myocardial infarction (NSTEMI) or
unstable angina patients, who are inappropriately discharged from hospital [6,7].
Electrical activity in the heart simultaneously produces a magnetic field [8], which can be
detected non-invasively using magnetocardiography (MCG) [9]. MCG is emission-free and of
very low risk to the patient [10]. Since magnetic fields are not attenuated by bodily tissue or
fluids, MCG is more sensitive than an ECG to very weak cardiac signals [11–13]; MCG can
detect ischemia-induced deviations in depolarization and repolarization with greater accuracy
than an ECG [14]. Substantial improvements in the diagnosis of ischemic events, such as
NSTEMI, which are difficult to detect by an ECG, have already been demonstrated with MCG
[13,15].
Superconducting Quantum Interference Device magnetometers have been widely used in
cardiology and neurology research [12,13]. However, they require separation from sources of
background interference, liquid helium cooling, highly trained operators, and have high run-
ning costs. A portable prototype magnetometer was recently designed to overcome the limita-
tions of existing technology [16]. Its novel coil configuration allows high sensitivity detection
with negligible background magnetic field interference [16]. The magnetometer can be used at
the patient’s bedside, making it suitable for use in acute and routine clinical settings. A techni-
cal performance study investigated the predictive performance and reliability of candidate pre-
dictors obtained from a broad spectrum of ischemic heart disease (IHD) patients and age-
matched healthy volunteers (S1 Text). The results showed an overall good discrimination per-
formance, with generally good to excellent reliability for the derived measurements.
In the current study, we assessed predictive ability of the measurements derived from the
magnetometer for the rule-out of healthy subjects and patients whose chest pain has a non-
ischemic origin from those with IHD.
Materials and methods
Data collection
MCG data were collected from two studies. A technical performance study was conducted in
patients (25 years) with suspected IHD and in healthy age-matched volunteers (S1 Text). A
subgroup of patients with NSTEMI within 3 days of enrollment was also recruited. Patients
were recruited from cardiology clinics at Leeds General Infirmary. Patients were identified
from medical records and approached by the Clinical Investigator during a clinic appointment
or on the hospital ward if the patient was an in-patient. Healthy volunteers were recruited by
poster advertising in the cardiology clinic.
A pilot clinical study was conducted in NSTEMI patients (18 years) requiring admission
for chest pain (troponin50 ng/L 12 h post-onset of chest pain), and in a control group of non-
IHD (NIHD) patients experiencing chest pain (ClinicalTrials.gov, number: NCT02359773,
available at: https://www.clinicaltrials.gov/ct2/show/NCT02359773). Patients with ST-elevated
myocardial infarction, hemodynamic instability, or revascularization were excluded from this
cohort. NIHD patients (18 years) were eligible if they had a referral due to chest pain in the
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last 8 weeks and a negative magnetic resonance imaging scan, Myoview, or a stress echocardio-
gram within 4 weeks of the first MCG scan. Patients with symptoms of ACS or troponin50
ng/L were excluded from this cohort.
Patients with a pacemaker or pregnant/lactating women were excluded. Additional exclu-
sion criteria included: internal cardiac defibrillator or active implantable device; metal
implants in the torso; and any comorbidity that prevented patients from being scanned. These
studies were approved by the relevant Institutional Review Board and all clinical investigations
were conducted according to the principles expressed in the Declaration of Helsinki. Written
informed consent was obtained prior to any study-related procedures. The technical perfor-
mance study was approved by the National Research Ethics Service (NRES) Committee York-
shire & The Humber—Leeds Central, with Ethics Certificate number 12/YH/0562. The pilot
clinical study was registered (protocol NCT02359773) on ClinicalTrials.gov., and approved by
the NRES Committee Yorkshire & The Humber—Leeds Central, with Ethics Certificate num-
ber 14/YH/1222.
An additional data set was collected from young (<30 years) healthy volunteers as a refer-
ence standard for a normal scan. Young healthy volunteers were recruited by poster advertis-
ing at the University of Leeds.
Data were grouped to allow differentiation of patients from controls: Group A (IHD
patients), Group B (controls), and Group C (young healthy volunteers).
MCG recordings
Scans were carried out for 10 min in a supine position in an unshielded room. Participants
removed upper garments and wore a hospital gown to minimize potential interference. For
NSTEMI patients, the scan was conducted within 48 h of the onset of chest pain and before
coronary angioplasty or other surgical intervention; for NIHD patients, the scan was com-
pleted within 4 weeks of a negative functional test for IHD.
MCG signals were baseline-corrected and averaged, centering on the R wave peak, to
increase the signal-to-noise ratio. A custom Python program was used to extract candidate
predictor estimates from the MCG data. The signal processing software also performed virtual
gradiometry and frequency domain filtering [16]. Ten MCG predictors were measured from
the ventricular depolarization phase (S1 Table; S1 Fig) [15,17,18].
Statistical analysis
Analysis of variance was used to compare the candidate MCG predictors between patients and
controls. Regularized logistic regression modeling [19] was employed to study the relationship
between the response variable (control vs patient) and the 10 candidate MCG predictors.
Model 1 was fitted on all available data with both Group B and Group C as controls. Model 2
included Group B only as a control, and Model 3 included Group C only as a control. The
patient group (Group A) was the same across all three models.
Several measures of predictive performance were reported [19]. The discriminatory ability
of the models to distinguish patients and controls was evaluated using the area under the
receiver operator characteristics curve (AUC). The AUC varies between 0.5 and 1.0, with a
higher value indicating better performance [20].
The ability of the models to rule-out subjects was assessed via sensitivity, specificity, and
negative predictive value (NPV) using a cut-off on the receiver operator characteristics at
which sensitivity exceeded 90%. These are defined in the confusion matrix given in Table 1.
The NPV is not intrinsic to the test and depend also on the prevalence of disease. Assuming
IHD prevalence of 15%, NPV is calculated using the following formula based on Bayes’
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theorem:
NPV ¼
specificity  ð1   prevalanceÞ
ð1   sensitivityÞ  prevalanceþ specificity ð1   prevalenceÞ
The models were internally validated using 10 times repeated 5-fold cross validation with
stratified sampling [20], whereby the model was developed on 80% of the data and tested on
the remaining 20%. The average performance was calculated over five repetitions and the
revised average value was viewed as a more accurate estimate of the model performance.
Statistical analysis was performed using R version 3.2.2 (R Core Team) statistical language.
Functions from the glmnet library for logistic regression and cross validation (glmnet and cv.
glmnet) were used.
Results
Participants
Between August 2013 and November 2015, 60 patients and 60 healthy volunteers were enrolled
in the technical performance study; an additional three patients were recruited to replace scan
malfunctions. The mean participant age was 64.2 years (± 10.79) and 37% were female (S2
Table). A total of 55/63 patients and 51/60 healthy volunteers were eligible for analysis (Fig 1).
Three patients had all MCG scans lost due to device malfunction, two patients had scans
excluded due to low signal-to-noise ratio, and three patient’s scans were all missing. Six healthy
volunteers were found to have a history of IHD, and three were missing all their MCG scans.
Between March 2015 and May 2015, 21 NSTEMI patients and 21 NIHD patients were
recruited to the pilot clinical study. The mean patient age was 59.0 years (± 12.71) and 44%
were female. A significant between-group difference was noted in gender distribution: 70% of
the NIHD patients were female versus 19% of the NSTEMI patients (P = 0.002; S3 Table]).
Patients with NSTEMI were significantly older than those with NIHD (mean difference –15.5
years; P<0.0001). Overall, 15/21 NSTEMI patients and 18/21 NIHD patients were eligible for
analysis (Fig 2). Three NSTEMI patients and two NIHD patients had scans excluded due to
low signal-to-noise ratio. A further three NSTEMI patients and one NIHD patient were
excluded from the analysis due to missing or corrupted MCG data.
Combined data set
Group A included 70 patients (55 patients from the technical performance study and 15
patients from the pilot clinical study). Group B included 69 controls (51 subjects from the tech-
nical performance study with no IHD as confirmed by an ECG and 18 subjects from the pilot
clinical study with non-ischemic chest pain and no IHD as confirmed by Myoview or a stress
echocardiogram). Group C consisted of 37 young healthy volunteers.
Table 1. Confusion matrix for a binary classifier.
Predicted
Positive Negative
Positive TP FN Sensitivity = TP/TP+FN
Negative FP TN Specificity = TN/TN+FP
TP = True positive: Diseased individuals correctly diagnosed as sick; FP = False positive: Healthy individuals wrongly predicted as sick; TN = True negative: Healthy
individuals correctly predicted as healthy; FN = False negative: Diseased individuals wrongly predicted as healthy.
https://doi.org/10.1371/journal.pone.0191241.t001
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Candidate MCG predictors
Of the 10 candidate MCG predictors, three showed a significant difference between patients
and controls (QR_peak and RS_peak, both P<0.01; RS_MMR, P<0.05; Table 2). Apart from
QR_interval and RS_interval, all of the remaining predictors showed a significant difference
between patients and young healthy volunteers. Fig 3 shows a representative histogram of the
RS_peak predictors.
Model performance
All logistic regression models showed respectable rule-out ability (Table 3). Model 1 yielded an
AUC of 0.82, specificity of 33.0%, sensitivity of 98.6%, and NPV for the ruling-out of patients
Fig 1. CONSORT Diagram: Technical performance study. Participant flow through the technical performance study. Data
were analyzed for 55/63 patients and 51/60 healthy controls.
https://doi.org/10.1371/journal.pone.0191241.g001
Fig 2. CONSORT Diagram: Pilot clinical study. Participant flow through the pilot clinical study. Data were analyzed for 15/
21 patients and 18/21 healthy controls.
https://doi.org/10.1371/journal.pone.0191241.g002
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of 99.3%. A near perfect separation between the groups was achieved in Model 3 comparing
patients with young healthy volunteers, with an AUC of 0.96 and specificity of 78.4% (sensitiv-
ity and NPV both 100%). Separation between the groups was lower in Model 2, with an AUC
of 0.75, specificity of 20.3%, and sensitivity of 94.3% (NPV 95.2%) due to the absence of young
healthy volunteers.
We noted optimism in the apparent performance of the models compared with the cross-
validated performance, which was similar across all models (Table 3).
Discussion
This study investigated the clinical performance of a portable prototype magnetometer to
effectively rule-out patients whose chest pain has a non-ischemic origin from those with IHD.
Table 2. Average value for each predictor for patient and control groups.
Predictor Group A: patients (n = 70) Group B: controls (n = 69) Group C: young healthy volunteers (n = 37)
QR_MMR 1.39 ± 0.53 1.35 ± 0.57 1.98 ± 0.92++
QR_angle 108.15 ± 15.59 110.78 ± 11.90 119 ± 8.67++
QR_interval 39.52 ± 5.52 39.49 ± 5.50 37.11 ± 6.97
QR_pd 11.44 ± 1.2 11.31 ± 0.78 9.63 ± 0.84++
QR_peak 33.88 ± 12.42 42.03 ± 13.35 70.44 ± 26.46++
RS_MMR 1.03 ± 0.46 0.88 ± 0.34 0.68 ± 0.23++
RS_angle –67.12 ± 15.02 –63.00 ± 11.44 –56.68 ± 9.63+
RS_interval 42.14 ± 6.80 42.18 ± 6.21 44.57 ± 8.97
RS_pd 11.48 ± 0.83 11.25 ± 0.74 9.79 ± 0.95++
RS_peak 37.50 ± 12.76 46.32 ± 14.94 88.29 ± 29.52++
 and  are used for the comparison between Group A and Group B, and Group A and Group C.
+ and ++ are used for the comparison between Group B and Group C. Significance level: +, P<0.05; ++, P<0.01.
https://doi.org/10.1371/journal.pone.0191241.t002
Fig 3. Histogram of the RS_peak predictors. A representative histogram of the RS_peak predictors for study participants
enrolled in Group A, Group B, and Group C.
https://doi.org/10.1371/journal.pone.0191241.g003
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In an ED and an outpatient setting, use of the magnetometer would have the potential to
reduce or negate the need for further tests in a subset of these non-ischemic patients.
Based on logistic regression Model 1, using an a priori cut-off of 0.2, the magnetometer
ruled-out 35.0% of the control group with 97.7% NPV. When utilized as part of the clinical
risk stratification, the ability to identify these patients could improve both outcomes and hos-
pital resource utilization.
Although almost 30% of patients presenting with chest pain are aged<50 years, the admis-
sion rate for this age group is the lowest amongst all ages [21], highlighting the particular need
to differentiate IHD from NIHD and non-cardiac chest pain in this group. Our results showed
remarkable discriminating capability of MCG between IHD patients and young healthy volun-
teers (Model 3), which is in-line with previous studies. Lim et al identified high discriminating
capability of MCG predictors between young control and patient groups [15]. In another
study, Kandori et al. reported a tendency of the maximum magnetic fields at the QRS complex
and T wave to decrease with age [17]. These observations are consistent with an age-related
decline in heart function.
The most significant MCG predictors in our analysis were ventricular depolarization predic-
tors. Researchers who focus on depolarization measures report diagnostic performance charac-
teristics of MCG that is substantially equivalent to, if not better than, those who do not [22].
A limitation of our analysis is that we did not consider the effect of gender on MCG. The
heterogeneous nature of the IHD patients in the technical performance study could also be a
limitation. In the subgroup of NSTEMI patients, MCG scans were recorded up to 3 days after
the index event, which could have negatively impacted the sensitivity and NPVs observed.
Enrollment of NSTEMI patients to the pilot clinical study relied exclusively on a raised tropo-
nin level, the assumption being that troponin is 100% sensitive and specific, which it is not
[23,24]. Similarly, recruitment of NIHD patients relied on a normal Myoview or a stress echo-
cardiogram result, neither of which have 100% sensitivity or specificity. Due to the nature of
the pilot clinical study it was not possible to implement consecutive recruitment, meaning that
Table 3. Apparent and cross-validation performance of the logistic regression models.
Model 1 Model 2 Model 3
Patient group Group A Group A Group A
Control group Group B + Group C Group B Group C
Penalty (alpha) 0.3 0.3 0.3
Apparent performance
AUC 0.82 0.75 0.96
Cut-off 0.20 0.30 0.30
Sensitivity, % 98.6 94.3 100
Specificity, % 33.0 20.3 78.4
NPV, %a 99.3 95.2 100
Cross-validation performance
AUC 0.78 0.65 0.94
Cut-off 0.20 0.30 0.30
Sensitivity, % 95.4 91.3 97.3
Specificity, % 35.0 27.6 69.1
NPV, %a 97.7 94.7 99.3
AUC, area under the receiver operator characteristic curve; NPV, negative predictive value
Group A, patients; Group B, controls; Group C, young healthy volunteers.
aBased on a disease prevalence of 15%.
https://doi.org/10.1371/journal.pone.0191241.t003
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selection bias could not be excluded. The healthy young volunteers were recruited from a uni-
versity campus with an average age<30 years, and thus they did not represent a typical young
person presenting to the ED. Finally, the total number of participants analyzed in the study
was small. Accurate estimation of the internal validity of a predictive model is problematic
when using such a small sample size [20].
In summary, the portable prototype magnetometer fills an unmet need for a rule-out test in
triaging chest pain patients to reduce the number of patients with a non-ischemic cause of
chest pain who go through screening and follow-up, which could ultimately improve patient
care and outcomes, and reduce resource utilization.
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